By Analysts predict packaged food manufacturers and fast-food eateries may be pushed to alter more of their goods next year when newly licensed appetite-suppressing GLP-1 tablets become accessible in January 2026.
The decision comes as more Americans are likely to try the medications in pill form rather than injections, owing to the lower cost and many patients’ reluctance to inject themselves.
The United States Food and Drug Administration authorised Novo Nordisk’s Wegovy GLP-1 tablet on Monday, sending food company shares lower on Tuesday.
Eli Lilly’s competing GLP-1 treatment is expected to receive regulatory approval next year, broadening access to the drug class.
According to Reuters, analysts see the approval as a watershed moment, as pills could dramatically expand the market for GLP-1 drugs and increase their use among consumers.
Changing eating habits puts pressure on food companies
Food corporations such as Conagra Brands and Nestlé are already dealing with shifts in consumer tastes caused by the popularity of weight-loss injections.
Shoppers are progressively gravitating toward higher-protein items and smaller portion sizes, which analysts predict will continue with the broad usage of GLP-1 tablets.
To react, corporations are promoting protein-rich foods, changing labels to characterise products as “GLP-1 friendly,” and cooperating with major retailers to sell such offerings better.
“We are seeing people cut (back) specifically on salty snacks, liquor, soda, drinks, and bakery snacks, and more focused on protein and fibre, so we expect food companies and also restaurants to cater to this audience that is growing,” commented JP Frossard, Rabobank consumer food analyst.
He added that increased access to GLP-1 medications will expand the addressable market for goods specifically designed for these users.
Andrew Rocco, a stock strategist at Zacks Investment Research, called Novo Nordisk’s tablet approval “groundbreaking,” saying that the oral version will be less expensive than the injectable Wegovy while providing the same weight-loss results.
“High protein, smaller portions, and functional food innovation will be necessary,” he said to Reuters.
Data show spending pullback on food
The potential impact is substantial. According to US government data, approximately 40% of American adults are fat, and approximately 12% currently use GLP-1 medications, according to a poll conducted last month by health policy research firm KFF.
According to a Cornell research published this week, households that use GLP-1 drugs spend an average of 5.3% less at grocery stores and almost 8% less at fast-food restaurants.
The study looked at purchase data from approximately 150,000 households obtained by Numerator.
When households stopped using the drug, the cost savings diminished significantly. Researchers expect the effects to become more widespread with the introduction of weight-loss drugs.
“The decreases we saw will most likely show up in a much broader slice of the population” as a result of weight-loss medications, said Sylvia Hristakeva, one of the study’s co-authors.
She went on to say that because tablets are less expensive and easier to take, people are more inclined to stick with them for longer periods of time.
Industry responds with protein and portions
While the Cornell study indicated only minor increases in spending on yoghurt and fresh fruit, food corporations are already changing their strategies.
Earlier this year, Conagra started labelling select Healthy Choice frozen meals as “GLP-1 friendly,” emphasising their high protein and fibre content.
A company spokeswoman stated that those meals are selling quicker than competitors making similar claims, and that Conagra intends to release more recipes with the same labelling in May.
The company also intends to market the products through partnerships with stores such as Walmart and Kroger.
Danone, a French dairy firm, reported a double-digit increase in its high-protein goods, notably Oikos Greek yoghurt, which has accelerated alongside GLP-1 use.
Nestlé has also introduced new frozen meals designed for GLP-1 users under the Vital Pursuit brand.
Restaurants are making similar approaches. Chipotle, a fast-casual restaurant company, has lately unveiled a “High Protein Menu,” which includes single cups of chicken or beef.
Other businesses, such as Olive Garden, have recently launched smaller, lower-priced portions.
According to Stephen Kennedy, marketing director at Noodles & Company, such enhancements are intended to provide customers with “options that satisfy without going overboard,” illustrating how GLP-1 medications are transforming not only diets but the entire food sector.
The post GLP-1 weight-loss pills set to reshape US food demand in 2026 appeared first on Invezz
